Literature DB >> 2569828

Plasma membrane-specific deficiency in cardiac beta-adrenergic receptor in streptozocin-diabetic rats.

A Kashiwagi1, Y Nishio, Y Saeki, Y Kida, M Kodama, Y Shigeta.   

Abstract

Cell surface [3H]CGP 12177 binding sites in 10-wk streptozocin-diabetic rats decreased by 41% (P less than 0.01) compared with that in the control rats. In contrast, there was no difference in the total cell receptor concentration between the control and the diabetic rats, which was measured by hydrophobic antagonist [125I]-iodocyanopindolol binding. Forty-eight-hour in vivo insulin treatment significantly (P less than 0.05) increased cell surface beta-adrenergic receptor concentration by 37% above that in diabetic rats without any change in total receptor concentration in the cells. However in vitro treatment of 8 nM insulin, 33 mM glucose, or 10 mM 3-hydroxybutyrate for 2 h showed no effect on [3H]CGP 12177 binding. In contrast, 10 microM isoproterenol-dependent decrease and the recovery of cell surface receptors after the removal of the agonist were significantly (P less than 0.01) impaired in diabetic rats compared with those of control rats. These results indicate that only cell surface beta-adrenergic receptors decrease in diabetic rats, which may be associated with abnormalities in the receptor distribution. The decrease in cell surface receptor number closely associates with the diabetic state and is reversed by the short-term insulin treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569828     DOI: 10.1152/ajpendo.1989.257.2.E127

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Pharmacologic characterization in vitro and in vivo of iodine 123-labeled derivatives of the beta-adrenoceptor antagonist CGP12177, designed for the imaging of cardiac beta-receptors.

Authors:  E A Dubois; G A Somsen; J C van den Bos; A G Janssen; G J Boer; H D Batink; E A van Royen; M Pfaffendorf; P A van Zwieten
Journal:  J Nucl Cardiol       Date:  1996 May-Jun       Impact factor: 5.952

Review 2.  Cross-Talk Between Insulin Signaling and G Protein-Coupled Receptors.

Authors:  Qin Fu; Qian Shi; Toni M West; Yang K Xiang
Journal:  J Cardiovasc Pharmacol       Date:  2017-08       Impact factor: 3.105

3.  Exercise training initiated after the onset of diabetes preserves myocardial function: effects on expression of beta-adrenoceptors.

Authors:  Keshore R Bidasee; Hong Zheng; Chun-Hong Shao; Sheeva K Parbhu; George J Rozanski; Kaushik P Patel
Journal:  J Appl Physiol (1985)       Date:  2008-06-26

4.  Mechanism of cardioprotective action of TNF-alpha in the isolated rat heart.

Authors:  Satyajeet S Rathi; Yan-Jun Xu; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2002

5.  Preclinical characterization of a novel radiolabeled analog of practolol for the molecular imaging of myocardial β-adrenoceptor density.

Authors:  Eric Carbonnelle; Véronique Josserand; Laurent M Riou; Olivier Ormezzano; Alexis Broisat; Pascale Perret; Gilles Barone-Rochette; Daniel Fagret; Catherine Ghezzi
Journal:  J Nucl Cardiol       Date:  2014-05-30       Impact factor: 5.952

6.  Post-receptor defect accounts for phosphorylase hypersensitivity in cultured diabetic cardiomyocytes.

Authors:  J A Buczek-Thomas; S R Jaspers; T B Miller
Journal:  Mol Cell Biochem       Date:  1992-11-04       Impact factor: 3.396

7.  Changes in adenosine sensitivity in the hippocampus of rats with streptozotocin-induced diabetes.

Authors:  P D Morrison; M W Mackinnon; J T Bartrup; P G Skett; T W Stone
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

8.  Altered sympathetic nervous system signaling in the diabetic heart: emerging targets for molecular imaging.

Authors:  James T Thackeray; Rob S Beanlands; Jean N Dasilva
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-20

Review 9.  The functional state of hormone-sensitive adenylyl cyclase signaling system in diabetes mellitus.

Authors:  Alexander O Shpakov; Kira V Derkach
Journal:  J Signal Transduct       Date:  2013-09-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.